PhD Scientific Days 2023

Clinical Medicine - Posters J

SARS-CoV2 Vaccination In Hungarian IPF Patients

Text of the abstract

Introduction: SARS-CoV2 infection is associated with significant risk of coronavirus disease (COVID-19) and represents a significant risk factor for functional deterioration in idiopathic pulmonary fibrosis (IPF) patients.

Methods: We retrospectively reviewed all IPF patients treated at our university center for their SARS-CoV2 vaccination status starting from January 2021.

Results: Total of 69 (out of treated 73 IPF patients) received minimum 2 doses of SARS-CoV2 vaccines (male 56.52%, age: 71.22 ± 9.65 years), 21 of them were vaccinated with non-mRNA vaccines (BBIBP-CorV-Sinopharm, ChAdOx1-AstraZeneca, Gam-Covid-Vac-Sputnik and Ad26.COV2.S-Janssen), while 48 mRNA vaccines. Most patients received BNT162b2-mRNA-Pfizer/Biontech (57.97%), followed by BBIBP-CorV-Sinopharm (15.94%) and mRNA-1273-Moderna (11.59%). Majority (N=57) of patients also took a third dose, mostly mRNA type (N=55), only 2 of them received a non-mRNA booster (Janssen). From all patients there was a total of 1 case of hospitalization and death due to COVID-19 pneumonia. This patient was vaccinated, but received no booster dose and more than 6 months passed between the vaccination and the COVID infection; she also received immunosupressive treatment at the time of the infection. No significant adverse event related to the vaccinations was reported in any patients. IPF patients were mainly in a good functional state (FVC = 2.2 [1.74-3.11] L; 78.24 ± 22.66%) with reduced diffusion capacity (TLCO = 4.56 [3.42-6.16] mmol/kPa/min; 61.23 ± 21.42%).

Conclusion: SARS-CoV2 vaccination is utmost important in IPF patients, and independent of vaccine type used it resulted in significantly decreased risk of COVID-19 hospitalization.